Ascendis Pharma A/S (ASND) News Today

Capital International Investors grew its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,191,312 shares of the biotechnology comp

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Analysts at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a note issued to investors on Tuesday, July 23rd. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology comp

Seven Eight Capital LP decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 75.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,597 shares of the biotechnology company's stock

Acadian Asset Management LLC grew its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1,461.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,492 shares of the biotechnology company's stock

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have assi

Sei Investments Co. trimmed its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 346,186 shares of the biotechnology company's stock after selling 15,644 shares during the period. Sei Investmen

TimesSquare Capital Management LLC lowered its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 27.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 575,698 shares of the biote

GSA Capital Partners LLP bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,564 shares of the biotechnology company's st

BNP Paribas Financial Markets lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4,231.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 75,540 shares of the biotechnology company's stock after purchasing an additional 73,7

Allspring Global Investments Holdings LLC cut its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 189,208 shares of the biotechnology company's sto

TD Cowen raised Ascendis Pharma A/S from a "hold" rating to a "buy" rating and boosted their price target for the stock from $156.00 to $175.00 in a report on Tuesday.

Goldman Sachs Group Inc. grew its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 422,854 shares of the biotechnology company's stock after purchasing an additional 12,881 shares

Wellington Management Group LLP lowered its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 85.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,248,293 shares of the biotechnology company's stock after selling 18,663,

Perceptive Advisors LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 132,176 shares of the

ADAR1 Capital Management LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 45,884 shares of the biotechnology company's stock, valued

Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 4.4%

Sei Investments Co. lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 8.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 361,830 shares of the biotechnology company's stock after selling 34

Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,755,555 shares of the biotechnology company's stock after buying an additional 85,55

Vestal Point Capital LP acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 625,000 shares of the biotechnology company's stock, valued at approximately $78,719,00

Seven Eight Capital LP purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 18,636 shares of the biotechnology company's stock,

Gray Foundation purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,700 shares of the biotechnolog

Affinity Asset Advisors LLC decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 56.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,000 shares of the biotechnology company

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 3,460,000 shares, a decrease of 6.5% from the April 30th total of 3,700,000 shares. Based on an average daily trading volume, of 370,500 shares, the short-interest ratio is currently 9.3 days.

Hsbc Holdings PLC purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 111,107 shares of the biotechnolo

Evoke Wealth LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 27,069 shares of the biotechnology company's stock, va

Trexquant Investment LP bought a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 9,868 shares of the biotechnology company's stock, valued at approximately $1,243,000. Other hedge funds

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating

Artisan Partners Limited Partnership cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,749,227 shares of the biotechnology

Westfield Capital Management Co. LP grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,030,634 sh

StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Thursday.

Ascendis Pharma A/S (NASDAQ:ASND) Trading 7% Higher

Matisse Capital grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 31.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,635 shares of the biotechnology com

First Turn Management LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 151,587 shares of the biotechnology compan

Cantor Fitzgerald reiterated an "overweight" rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a report on Wednesday.